Welcome to our dedicated page for Nano Dimension news (Ticker: NNDM), a resource for investors and traders seeking the latest updates and insights on Nano Dimension stock.
Nano Dimension Ltd. reports news about digital manufacturing operations, product-line performance, financial results, and corporate portfolio actions. Company updates commonly reference Markforged, Essemtec, additive manufacturing, surface-mount technology, industrial inkjet printing, and the role of software and materials in its manufacturing systems.
Nano Dimension news also covers strategic alternatives, cost-management actions, shareholder meetings, ADS-related governance matters, and its transition from foreign private issuer reporting to U.S. domestic periodic reporting. Recent corporate updates have included product-line monetization, a limited-duration shareholder rights agreement, and annual meeting results.
Nano Dimension (Nasdaq: NNDM) appointed Nadav Kidron to its Board of Directors and plans to form a new Strategy and Capital Allocation Committee as part of an ongoing strategic review led by Chairman Phillip Borenstein.
Kidron, President and CEO of Oramed Pharmaceuticals (Nasdaq: ORMP) and a director at Alpha Tau Medical (Nasdaq: DRTS) and Lifeward (Nasdaq: LFWD), will chair the committee. According to Nano Dimension, the committee will help evaluate capital allocation alternatives, potential returns of excess capital to shareholders, monetization of non-core assets and other strategic opportunities aimed at maximizing long-term shareholder value.
Nano Dimension (Nasdaq: NNDM) reported second quarter 2026 revenue of $29.0 million, up 12.1% year-over-year from $25.8 million, driven mainly by growth in the Essemtec product line. Markforged contributed $14.1 million, down $2.0 million versus the prior-year period.
GAAP gross profit rose 88.8% to $13.3 million, with gross margin improving to 45.9% from 27.3%. Adjusted gross margin increased to 48.8% from 44.7%. Net loss from continuing operations improved to $6.8 million from $11.4 million, and Adjusted EBITDA loss from continuing operations improved to $9.6 million from $16.7 million. Total cash, cash equivalents, deposits, restricted deposits and marketable equity securities were $433.3 million as of June 30, 2026.
The company agreed to sell MarkForged, Inc. to Stratasys for $42.5 million in cash and completed the sale of its AME and Fabrica product lines for up to $12.5 million. Together with a headquarters lease termination, ongoing strategic actions are expected to reduce annualized cash burn by approximately $25 million. Nano Dimension also refreshed its Board following a settlement with Murchinson, appointed Moshe Rozenbaum as Interim CEO, suspended 2026 guidance, and will not host a Q2 2026 earnings call.
Nano Dimension (Nasdaq: NNDM) appointed Moshe Rozenbaum as Interim Chief Executive Officer, effective immediately, and named Phillip Borenstein as Chairman of the Board. According to Nano Dimension, Rozenbaum will work with the Board and leadership team to support business continuity while strategic priorities and opportunities are evaluated.
Nano Dimension (Nasdaq: NNDM) and Murchinson jointly entered a settlement agreement on July 17, 2026, ahead of Nano Dimension’s planned July 31, 2026 Extraordinary General Meeting. The July EGM will be cancelled, four incumbent directors resigned, and three Murchinson-nominated directors were appointed to the board.
Nano Dimension (Nasdaq: NNDM) entered into an agreement to terminate the lease for its current corporate headquarters, effective December 31, 2026. The long-term lease was originally signed by MarkForged in 2021 and was scheduled to run through 2031.
According to Nano Dimension, termination of the lease is expected to eliminate approximately $38 million of cumulative future lease costs through 2031. After an estimated $13 million lease termination payment, the company expects about $25 million in cumulative net cash savings, supporting broader initiatives to reduce cash burn and strengthen its financial position. The company previously indicated that the sale of MarkForged was expected to reduce annualized cash burn by roughly $15 million, including about $7.5 million of annualized lease-related savings tied to this headquarters lease.
Summary not available.
Nano Dimension (Nasdaq:NNDM) provided more detail on its proposed business combination with Infinite Epigenetics, an operating epigenetic diagnostics business.
Infinite has a CLIA-certified methylation lab, a network of 7,500+ healthcare providers, over 120,000 epigenetic samples, 50+ peer-reviewed studies, and commercial revenue. The transaction would pivot Nano from 3D printing to AI-driven preventive health and diagnostics and, according to the company, values Nano at net cash plus a 20% premium through ownership in the combined entity. Nano expects to receive two board seats in the merged company, with any definitive agreement to be put to a shareholder vote.
Summary not available.
Nano Dimension (Nasdaq:NNDM) signed a non-binding term sheet to combine with Infinite Epigenetics, creating a publicly traded, AI-powered preventive health and diagnostics company targeting a $90B+ U.S. clinical diagnostics market.
The deal values Infinite Epigenetics at $890 million. Existing Nano shareholders are expected to hold a meaningful minority stake, based on a stated value reflecting a 20% premium to Nano’s estimated net cash at closing and a contingent value right on legacy assets. The combined company is expected to have over $400 million in cash and trade on Nasdaq as “IEAI,” with Infinite CEO Dr. Matthew Dawson leading.
Summary not available.